Tonix Pharmaceuticals Holding Corp. (TNXP)
| Market Cap | 3.30M |
| Revenue (ttm) | 12.46M |
| Net Income (ttm) | -149.01M |
| Shares Out | 22.00M |
| EPS (ttm) | -75.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,905,012 |
| Open | 0.148 |
| Previous Close | 0.150 |
| Day's Range | 0.145 - 0.148 |
| 52-Week Range | 0.130 - 26.880 |
| Beta | 2.10 |
| Analysts | Strong Buy |
| Price Target | 53.50 (+35,566.67%) |
| Earnings Date | Nov 7, 2024 |
About TNXP
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cycl... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $53.5, which is an increase of 35,566.67% from the latest price.
News
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- ...
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...
Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
The World Health Organization (WHO) released its preferred target product profile (TPP) criteria for mpox vaccines at its Mpox Research and Innovation Scientific Conference held August 29-30
Penny stocks analysis: AITX, Intelligent Bio (INBS), Tonix (TNXP)
Penny stocks could see some more volatility in the coming months as the Federal Reserve starts cutting interest rates later this month. Historically, many traders tend to rotate to these companies whe...
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream
As Research into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets it with FDA-Fast Track-Designated TNX-102 SL
CHATHAM, NJ / ACCESSWIRE / September 4, 2024 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with finan...
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL's potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and posttraumatic stress disorder...
Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
On Monday, Tonix Pharmaceuticals Holding Corp. TNXP and Bilthoven Biologicals collaborated to advance TNX-801, Tonix's mpox vaccine candidate.
Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix's Mpox Vaccine, TNX-801
World Health Organization declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) for the second time in two years
Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...
Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
On track to submit NDA in second half 2024 for TNX-102 SL for fibromyalgia; completed successful pre-NDA meetings with FDA in second quarter 2024
Tonix Pharmaceuticals Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, TNX-801, as WHO Declares Mpox Outbreak a Global Health Emergency
World Health Organization (WHO) has declared spread of mpox in multiple African countries a public health emergency of international concern (PHEIC) 1
FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations ...
Tonix Pharmaceuticals Announces Potential Positive Impact of the U.S. National Academies (NASEM) New Definition of Long COVID on the Size of the Fibromyalgia Market for Tonmya™
Fibromyalgia is a “diagnosable condition” in people suffering from Long COVID according to NASEM 1
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
CHATHAM, NJ / ACCESSWIRE / July 24, 2024 / From anthrax to the plague, biological warfare is a real threat to U.S. forces and civilians, so much so the Pentagon budgeted about $2 billion for the count...
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
CHATHAM, NJ / ACCESSWIRE / July 17, 2024 / With the completion of its final pre-NDA meeting with the FDA, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced it is filing an NDA submission in ...
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
CHATHAM, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced the closin...
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
CHATHAM, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has ent...
Tonix Pharmaceuticals Announces Proposed Public Offering
CHATHAM, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced that it in...
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia
Tonmya is a potential new first-line, centrally acting non-opioid analgesic for the management of fibromyalgia Approximately 10 million adults in the U.S. are affected by fibromyalgia, predominantly w...
Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program
Defense Threat Reduction Agency (DTRA) contract is expected to advance development of Tonix's broad-spectrum oral antiviral program TNX-4200 for medical countermeasures Defense Threat Reduction Agency...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has re...
Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024
Tonix's live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose
Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
CHATHAM, N.J., June 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biopharmaceutical company, today announced it has ent...